卫光生物拟合资设立项目公司 建设深圳市细胞与基因治疗市场化公共服务平台

Core Viewpoint - The company is establishing a joint venture, Shenzhen Xihe Life Technology Co., Ltd., to create a public service platform for cell and gene therapy (CGT) in Shenzhen, aiming to enhance the CGT market's development and innovation [1][2] Group 1 - The initial registered capital of the joint venture is set at 100 million yuan, with the company contributing 40 million yuan, representing a 40% equity stake [1] - The project focuses on building a market-oriented public service platform for CGT, emphasizing the entire industry chain from plasmid to viral vectors and cell drugs [1] - The platform aims to comply with GMP standards, break industry bottlenecks, lower entry barriers, accelerate technology transfer, and create a sustainable business ecosystem [1] Group 2 - This initiative is a strategic move for the company to extend its core advantages from the blood products sector into the forefront of biomedicine [2] - The project is expected to enhance the company's strategic layout in the biomedicine field, cultivate new business growth points, and strengthen its competitive edge [2] - It serves as a crucial lever for the company to achieve strategic upgrades and promote high-quality development [2]